Amundi Sage Therapeutics, Inc. Transaction History
Amundi
- $239 Billion
- Q1 2024
Shares
2 transactions
Others Institutions Holding SAGE
# of Institutions
222Shares Held
52.7MCall Options Held
207KPut Options Held
191K-
Vanguard Group Inc Valley Forge, PA5.75MShares$62 Million0.0% of portfolio
-
Rtw Investments, LP New York, NY5.48MShares$59.1 Million1.65% of portfolio
-
Black Rock Inc. New York, NY4.89MShares$52.7 Million0.0% of portfolio
-
Wellington Management Group LLP Boston, MA4.75MShares$51.2 Million0.02% of portfolio
-
State Street Corp Boston, MA4.49MShares$48.5 Million0.0% of portfolio
About Sage Therapeutics, Inc.
- Ticker SAGE
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,422,300
- Market Cap $641M
- Description
- Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...